In vitro correlates of HIV-2-mediated HIV-1 protection
Open Access
- 6 June 2000
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (12) , 6797-6802
- https://doi.org/10.1073/pnas.97.12.6797
Abstract
A prospective study of high-risk commercial sex workers in Senegal has shown that HIV-2 infection may reduce the risk of subsequent HIV-1 infection; these findings have been confirmed and extended, now with 13 years of observation. While exploring the biological mechanisms behind this natural protection, we found that a significant proportion of peripheral blood mononuclear cells obtained from HIV-2-infected subjects resisted in vitro challenge with CCR5-dependent HIV-1 viruses but not CXCR4-dependent viruses. High levels of β-chemokines, the natural ligands of the CCR5 coreceptor, were correlated with low levels of viral replication, and resistance was abrogated by antibodies to β-chemokines. Our results suggest that β-chemokine-mediated resistance may be an important correlate of HIV protection against HIV-1 infection and relevant to HIV vaccine design.Keywords
This publication has 40 references indexed in Scilit:
- Resistance to Human Immunodeficiency Virus Type 1 In Vitro as a Surrogate of Vaccine?Induced Protective ImmunityThe Journal of Infectious Diseases, 2000
- HIV-1 and HIV-2 dual infectionAIDS, 1998
- Receptor interference mediated by the envelope glycoproteins of various HIV-1 and HIV-2 isolatesVirus Research, 1996
- The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 IsolatesPublished by Elsevier ,1996
- CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1Science, 1996
- A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion CofactorsCell, 1996
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995
- Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1Science, 1994
- Cost-effective diagnosis of HIV-1 and HIV-2 by recombinant-expressed env peptide (566/996) dot-blot analysisAIDS, 1993
- HIV-2 antisera cross-neutralize HIV-1AIDS, 1988